Ginkgo Bioworks Holdings, Inc.
$7.98
▲
1.62%
2026-04-21 06:27:01
www.ginkgo.bio
NYQ: DNA
Explore Ginkgo Bioworks Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$492.71 M
Current Price
$7.98
52W High / Low
$17.58 / $5.37
Stock P/E
—
Book Value
$8.74
Dividend Yield
—
ROCE
-29.68%
ROE
-51.08%
Face Value
—
EPS
$-5.64
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
485
Beta
1.57
Debt / Equity
86.49
Current Ratio
4.92
Quick Ratio
4.92
Forward P/E
-1.78
Price / Sales
2.35
Enterprise Value
$392.7 M
EV / EBITDA
-1.47
EV / Revenue
2.31
Rating
None
Target Price
$8.67
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Jyong Biotech Ltd. | $2.31 | — | $185.51 M | — | 35.69% | 8.55% | $67 / $1.43 | $-0.31 |
| 2. | Oramed Pharmaceuticals Inc. | $3.83 | 3.45 | $151.27 M | 0% | -7.12% | 37.1% | $3.96 / $1.98 | $4.98 |
| 3. | BiomX Inc. | $1.46 | — | $9.55 M | — | -101.67% | -3.17% | $14.71 / $1.5 | $-12.5 |
| 4. | Aclaris Therapeutics, Inc. | $4.25 | — | $512.53 M | — | -53.3% | -50.2% | $4.89 / $1.08 | $0.85 |
| 5. | Silexion Therapeutics Corp | $1.08 | — | $3.63 M | — | -260.98% | 1718.9% | $22.36 / $0.97 | $0.83 |
| 6. | Veru Inc. | $2.43 | — | $39 M | — | -161.13% | -60.25% | $7.4 / $2.06 | $2.31 |
| 7. | MindWalk Holdings Corp. | $1.27 | — | $59.32 M | — | -34.42% | -58.82% | $3.25 / $0.4 | $0.23 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 33.4 M | 38.84 M | 49.6 M | 48.32 M | 43.85 M | — |
| Operating Profit | -70.05 M | -88.27 M | -61.87 M | -83.69 M | -99.45 M | — |
| Net Profit | -80.75 M | -80.75 M | -60.3 M | -90.96 M | -107.53 M | — |
| EPS in Rs | -1.62 | -1.62 | -1.21 | -1.82 | -2.15 | -1.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 170.16 M | 227.04 M | 251.46 M | 477.71 M |
| Operating Profit | -303.88 M | -487.73 M | -768.2 M | -2.21 B |
| Net Profit | -312.76 M | -547.03 M | -892.87 M | -2.1 B |
| EPS in Rs | -6.26 | -10.95 | -17.88 | -42.15 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.12 B | 1.38 B | 1.67 B | 2.54 B |
| Total Liabilities | 611.11 M | 661.39 M | 568.19 M | 803.04 M |
| Equity | 508.59 M | 716.06 M | 1.1 B | 1.74 B |
| Current Assets | 471.84 M | 602.74 M | 1 B | 1.45 B |
| Current Liabilities | 95.97 M | 107.27 M | 163.86 M | 172.96 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -171.06 M | -319.58 M | -295.5 M | -252.2 M |
| Investing CF | -240.29 M | -62.24 M | -80.69 M | -67.39 M |
| Financing CF | 17.77 M | -1.74 M | -3.22 M | 95.34 M |
| Free CF | -178.72 M | -382.13 M | -336.3 M | -304.47 M |
| Capex | -7.67 M | -62.54 M | -40.8 M | -52.27 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -9.71% | -47.36% | — | — |
| Earnings Growth % | 38.73% | 57.58% | — | — |
| Profit Margin % | -240.94% | -355.08% | -440.63% | — |
| Operating Margin % | -214.82% | -305.5% | -462.41% | — |
| Gross Margin % | 80.38% | 78.52% | 57.25% | — |
| EBITDA Margin % | -213.35% | -327.03% | -435.15% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-08-20 | 1:0.025 |